PortfoliosLab logoPortfoliosLab logo
ISIN
US85205L1070
CUSIP
85205L107
IPO Date
Jun 5, 1987

Highlights

Total Revenue (TTM)
$219.67M
Gross Profit (TTM)
$204.80M
EBITDA (TTM)
-$263.55M
Year Range
$46.71 - $47.02

Share Price Chart


Loading charts...

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Performance

SWTX Performance Chart


Loading charts...

S&P 500 Index

Returns By Period


SpringWorks Therapeutics, Inc.

1D
1M
YTD
6M
1Y
3Y*
5Y*
10Y*

Benchmark (S&P 500 Index)

1D
-0.74%
1M
4.90%
YTD
10.35%
6M
10.28%
1Y
26.52%
3Y*
20.83%
5Y*
12.30%
10Y*
13.66%
*Multi-year figures are annualized to reflect compound growth (CAGR)

SWTX Monthly Returns History


JanFebMarAprMayJunJulAugSepOctNovDecTotal
20253.79%54.03%-23.60%4.92%0.89%0.60%0.00%30.06%
202420.90%11.62%-0.08%-5.14%-11.20%-9.14%-4.67%16.15%-23.18%-5.96%37.67%-12.90%-1.01%
202320.72%1.59%-19.31%-9.17%17.11%-4.24%19.68%-10.20%-17.96%-0.95%32.71%20.11%40.33%
2022-10.16%1.63%-0.27%-23.97%-55.86%29.99%21.36%-7.06%2.74%-15.84%0.71%7.57%-58.03%
202114.88%3.29%-14.50%-2.32%13.47%1.07%3.99%-12.37%-15.53%5.71%7.14%-13.74%-14.53%

Benchmark Metrics

SpringWorks Therapeutics, Inc. has an annualized alpha of 26.34%, beta of 1.08, and R2 of 0.10 versus S&P 500 Index. Calculated based on daily prices since September 16, 2019.

  • This stock participates in less of S&P 500 Index's moves in both directions, but captures a larger share of gains (61.80%) than losses (51.79%) - typical of diversified or defensive assets.
  • R2 of 0.10 means this stock moves largely independently of S&P 500 Index - capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.

Alpha
26.34%
Beta
1.08
0.10
Upside Capture
61.80%
Downside Capture
51.79%

Return for Risk

Return / Risk — by metrics

The table below present risk-adjusted performance metrics for SpringWorks Therapeutics, Inc. (SWTX) and compare them to S&P 500 Index.


Risk / return metrics aren't available yet — we need at least 12 months of trading data to calculate them.

Dividends

Dividend History


SpringWorks Therapeutics, Inc. doesn't pay dividends

Drawdowns

Drawdowns Chart

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.


Loading charts...

Worst Drawdowns

The table below displays the maximum drawdowns of the SpringWorks Therapeutics, Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the SpringWorks Therapeutics, Inc. was 80.38%, occurring on May 27, 2022. The portfolio has not yet recovered.


Related event

Drawdown

Fall

Recovery

Underwater

Bear market2022
-80.38%May 2022
1y 3mo
5y 3moFeb 2021 - now
COVID crash2020
-50.40%Mar 2020
12d2mo 25d
3mo 7dMar 2020 - Jun 2020
2019 bear market2019
-36.23%Nov 2019
1mo 21d26d
2mo 17dSep 2019 - Dec 2019
2020 bear market2020
-25.59%Jul 2020
24d2mo 7d
3mo 1dJun 2020 - Sep 2020
COVID crash2020
-22.95%Feb 2020
1mo 16d21d
2mo 7dDec 2019 - Mar 2020

Drawdown Indicators


SWTXBenchmarkDifference

Max Drawdown

Largest peak-to-trough decline

-56.78%

Max Drawdown (1Y)

Largest decline over 1 year

-9.10%

Max Drawdown (3Y)

Largest decline over 3 years

-18.90%

Max Drawdown (5Y)

Largest decline over 5 years

-25.43%

Max Drawdown (10Y)

Largest decline over 10 years

-33.92%

Current Drawdown

Current decline from peak

-0.74%

Average Drawdown

Average peak-to-trough decline

-10.72%

Ulcer Index

Depth and duration of drawdowns from previous peaks

1.97%

Volatility

Volatility Chart

The chart below shows the rolling one-month volatility.


Loading charts...

Financials

Financial Performance

The chart below illustrates the trends in the financial health of SpringWorks Therapeutics, Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.


Annual
Quarterly

0.0

Valuation

The Valuation section provides an overview of how SpringWorks Therapeutics, Inc. is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.


Income Statement



TTM
Revenue

Total Revenue

Cost Of Revenue

Gross Profit

Operating Expenses

Selling, General & Admin Expenses

R&D Expenses

Depreciation And Amortization

Total Operating Expenses

Income

Income Before Tax

Operating Income

EBITDA

EBIT

Earnings From Continuing Operations

Net Income

Income Tax Expense

Other Non-Operating Income (Expenses)

Extraordinary Items

Discontinued Operations

Effect Of Accounting Charges

Non Recurring

Minority Interest

Other Items

Interest Income

Interest Expense

Net Interest Income

Values in undefined except per share items
Portfolio Analyzer

Build a portfolio with SWTX

Add SpringWorks Therapeutics, Inc. to a portfolio and analyze allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.

Open Portfolio Analyzer with SWTX